Title: Survival analysis of stage II gastric cancer patients after D2 gastrectomy: A Chinese
people-based research
Version: 2 Date: 07 May 2021
Reviewer's report:
The authors aimed to confirm the role of adjuvant chemotherapy in the treatment of stage
II gastric cancer and determine some prognostic factors for the establishment of a prediction
model to guide individualized treatment for stage II gastric cancer. They concluded that adjuvant
chemotherapy can improve OS in stage II gastric cancer patients. In addition, Tumor size,
CEA, and N stage are prognostic factors, and age, tumor location, and T stage are independent
prognostic factors, thus providing significant evidence for doctors to identify patients with poor
prognosis and helping guide individual therapy. In the first place, the ACTS-GC study and the
CLASSIC study both concluded that adjuvant chemotherapy for patients with Stage II/III gastric
cancer was confirmed to improve prognosis. The subgroup analyses in both studies revealed that
prognosis of patients with Stage II gastric cancer significantly improved in the final analyses.
Therefore, the first aim and the first conclusion are nonsense. Moreover, to achieve the second
purpose, the authors should propose some examples of which patient should receive adjuvant
chemotherapy and which patient should not.
Stage II in TNM 8 is not identical to that used in the ACTS-GC and the CLASSC studies. The
most important difference is that the tumors with subserosa invasion is classified to T3 in the
TNM8 while those were classified to T2. This difference should be addressed and considered
in the manuscript.
Title: Survival analysis of stage II gastric cancer patients after D2 gastrectomy: A Chinese
people-based research
Version: 2 Date: 07 May 2021
Reviewer's report:
The authors aimed to confirm the role of adjuvant chemotherapy in the treatment of stage
II gastric cancer and determine some prognostic factors for the establishment of a prediction
model to guide individualized treatment for stage II gastric cancer. They concluded that adjuvant
chemotherapy can improve OS in stage II gastric cancer patients. In addition, Tumor size,
CEA, and N stage are prognostic factors, and age, tumor location, and T stage are independent
prognostic factors, thus providing significant evidence for doctors to identify patients with poor
prognosis and helping guide individual therapy. In the first place, the ACTS-GC study and the
CLASSIC study both concluded that adjuvant chemotherapy for patients with Stage II/III gastric
cancer was confirmed to improve prognosis. The subgroup analyses in both studies revealed that
prognosis of patients with Stage II gastric cancer significantly improved in the final analyses.
Therefore, the first aim and the first conclusion are nonsense. Moreover, to achieve the second
purpose, the authors should propose some examples of which patient should receive adjuvant
chemotherapy and which patient should not.
Stage II in TNM 8 is not identical to that used in the ACTS-GC and the CLASSC studies. The
most important difference is that the tumors with subserosa invasion is classified to T3 in the
TNM8 while those were classified to T2. This difference should be addressed and considered
in the manuscript.
Please review this paper.
user
Title: Survival analysis of stage II gastric cancer patients after D2 gastrectomy: A Chinese
people-based research
Version: 2 Date: 07 May 2021
Reviewer's report:
The authors aimed to confirm the role of adjuvant chemotherapy in the treatment of stage
II gastric cancer and determine some prognostic factors for the establishment of a prediction
model to guide individualized treatment for stage II gastric cancer. They concluded that adjuvant
chemotherapy can improve OS in stage II gastric cancer patients. In addition, Tumor size,
CEA, and N stage are prognostic factors, and age, tumor location, and T stage are independent
prognostic factors, thus providing significant evidence for doctors to identify patients with poor
prognosis and helping guide individual therapy. In the first place, the ACTS-GC study and the
CLASSIC study both concluded that adjuvant chemotherapy for patients with Stage II/III gastric
cancer was confirmed to improve prognosis. The subgroup analyses in both studies revealed that
prognosis of patients with Stage II gastric cancer significantly improved in the final analyses.
Therefore, the first aim and the first conclusion are nonsense. Moreover, to achieve the second
purpose, the authors should propose some examples of which patient should receive adjuvant
chemotherapy and which patient should not.
Stage II in TNM 8 is not identical to that used in the ACTS-GC and the CLASSC studies. The
most important difference is that the tumors with subserosa invasion is classified to T3 in the
TNM8 while those were classified to T2. This difference should be addressed and considered
in the manuscript.
assistant